Concentric reversible visual field loss, nyctalopia, and dyschromatopsia with ezetimibe therapy

Zhengchao Xu*, Veronica Preda, James Jabbour

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

24 Downloads (Pure)

Abstract

This is a case of ezetimibe-induced concentric field loss, dyschromatopsia, and nyctalopia in a patient with no prior history of retinal dystrophy or drug hypersensitivity. A 55-year-old Caucasian woman presents with a 1-year history of increasing concentric visual field loss, nyctalopia, photophobia, and colour vision impairment. These symptoms correlated with the commencement of ezetimibe therapy 10 mg daily for hypercholesterolaemia. She demonstrated repeatable bilateral visual field constriction on 30-2 Humphrey visual filed testing and colour vision impairment on Ishihara plates (OD: 1/17, OS: 1/17). Biochemical and radiological screening for carcinoma-associated retinopathy was unremarkable. A working diagnosis of drug-induced rod-cone dysfunction was made. Her visual symptoms and field changes completely resolved 3 months after cessation of ezetimibe therapy. This case suggests that ezetimibe is a potential cause of rod-cone dysfunction and should be considered as a differential in patients with new unexplained visual symptoms.

Original languageEnglish
Pages (from-to)185-193
Number of pages9
JournalCase Reports in Ophthalmology
Volume14
Issue number1
DOIs
Publication statusPublished - 28 Apr 2023

Bibliographical note

Copyright the Author(s) 2023. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

Keywords

  • Case report
  • Dyschromatopsia
  • Ezetimibe
  • Nyctalopia
  • Visual field
  • Visual impairment

Fingerprint

Dive into the research topics of 'Concentric reversible visual field loss, nyctalopia, and dyschromatopsia with ezetimibe therapy'. Together they form a unique fingerprint.

Cite this